Increased expression of histone deacetylase 2 is found in human gastric cancer
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Accumulated evidence has established that aberrant regulation of histone deacetylases (HDACs) is one of the major causes of the development of human malignancies. Among different iso‐enzymes of HDAC and sirtuins grouped as the HDAC super family, little is known as to how histone deacetylase 2 (HDAC2) causes carcinogenesis in solid tumors. Here, in order to investigate the possible role of HDAC2 in gastric carcinogenesis, we analyzed the expression of HDAC2 in 71 gastric adenocarcinomas by immunohistochemistry. Moderate to strong expression of HDAC2 was found in 44 (62%) out of a total of 71 tumors. The majority of positive tumors, which were detected in the nucleus but not in normal gastric epithelium, did not express HDAC2 or showed only weak positive staining. Interestingly, we also noted that HDAC2 expression appeared to be associated with tumor aggressiveness as HDAC2 expression was observed to be statistically significant in advanced gastric cancer (P=0.0023, Chi‐square test) and in positive lymph node metastasis (P=0.0713, Chi‐square test). Taken together, these results suggest that HDAC2 may play an important role in the aggressiveness of gastric cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510 · cited 1×
“HDACs comprise class I and II enzymes of the deacetylase superfamily, and the class III enzymes (sirtuins) are HDACs in yeast (13, 14).”
BackgroundParkin, D. M., Pisani, P., & Ferlay, J. (1999) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.49.1.33 · Cited by 3,376
Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins
Frye, R. A. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3000 · Cited by 1,409
Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
Pisani, P., Parkin, D. M., Bray, F., & Ferlay, J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19991210)83:6<870::aid-ijc35>3.0.co;2-9 · Cited by 860
Fuchs, C. S., & Mayer, R. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199507063330107 · Cited by 559
Gui, C.-Y., Ngo, L., Xu, W. S., Richon, V. M., & Marks, P. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307708100 · Cited by 550
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis
Zhu, P., Martin, E., Mengwasser, J., Schlag, P., Janssen, K.-P., & Göttlicher, M. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00114-x · Cited by 525
Yang, W.-M., Yao, Y.-L., Sun, J.-M., Davie, J. R., & Seto, E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.44.28001 · Cited by 438
beta-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer.
Clements, W. M., Wang, J., Sarnaik, A. A., Kim, O. J., MacDonald, J., Fenoglio‐Preiser, C. M., Groden, J. L., & Lowy, A. M. (2002) · PubMed · Cited by 411
Histone deacetylase inhibitors: Understanding a new wave of anticancer agents
Villar‐Garea, A., & Esteller, M. (2004) · International Journal of Cancer · doi:10.1002/ijc.20372 · Cited by 247
Life (and death) in a malignant tumour
Kinzler, K. W., & Vogelstein, B. (1996) · Nature · doi:10.1038/379019a0 · Cited by 198
The impact of chromatin in human cancer: linking DNA methylation to gene silencing
Ballestar, E., & Esteller, M. (2002) · Carcinogenesis · doi:10.1093/carcin/23.7.1103 · Cited by 143
Somatic mutations of the trefoil factor family 1 gene in gastric cancer
Park, W. S., Oh, R. R., Park, J. Y., Lee, J. H., Shin, M. S., Kim, H. S., Lee, H. K., Kim, Y. S., Kim, S. Y., Lee, S. H., et al. (2000) · Gastroenterology · doi:10.1053/gast.2000.16483 · Cited by 140
Self-citationUh, W., & Grossmann, A. (2000) · PubMed · Cited by 131
Inactivating mutations of the caspase-10 gene in gastric cancer
Park, W. S., Lee, J., Shin, M. S., Park, J. Y., Kim, H. S., Lee, J. H., Kim, Y. S., Lee, S. H., Xiao, W., Park, C. H., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205394 · Cited by 93
Self-citationEarly gastric cancer: Report of 58 cases
Oliveira, F. J., Ferrão, H., Furtado, E., Batista, H., & Conceição, L. (1998) · Gastric Cancer · doi:10.1007/s101200050054 · Cited by 56
Cited by
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Sharma, S., Kelly, T. K., & Jones, P. A. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp220 · Cited by 2,637
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
“High levels of HDAC2 were found in colorectal, cervical and gastric cancers [9,10].”
BackgroundHistone deacetylases and cancer
Glozak, M. A., & Seto, E. (2007) · Oncogene · doi:10.1038/sj.onc.1210610 · Cited by 1,031
Metadata
- Authors
- SONG, J., NOH, J. H., LEE, J. H., EUN, J. W., AHN, Y. M., KIM, S. Y., LEE, S. H., PARK, W. S., YOO, N. J., LEE, J. Y., & NAM, S. W.
- Venue
- APMIS
- Publisher
- Wiley
- Published
- 2005-04
- Volume
- 113
- Issue
- 4
- Pages
- 264-268
- ISSN
- 0903-4641 (ISSN-L)
- 1600-0463
- OpenAlex
- W2008054969
- Cited by
- 346
- References
- 19
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.